Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma
Jedd D. Wolchok(Cornell University), Jianda Yuan, Susan E. Krown(Memorial Sloan Kettering Cancer Center), Melanie Heywood(Memorial Sloan Kettering Cancer Center), Miguel‐Angel Perales(Memorial Sloan Kettering Cancer Center), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), P O Livingston(Memorial Sloan Kettering Cancer Center), Teresa Rasalan, Humilidad F. Gallardo(Memorial Sloan Kettering Cancer Center), J. Wang(Memorial Sloan Kettering Cancer Center)
Cited by 6
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k